ABILIFY MYCITE - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

ABILIFY MYCITE

CRITERIA

Trial of generic aripiprazole. Step applies to new starts only. Approve for continuation of prior therapy.

ANTIDEPRESSANTS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

APLENZIN, DESVENLAFAXINE ER, EMSAM, FETZIMA

CRITERIA

Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine. Approve for continuation of prior therapy.

ATYPICAL ANTIPSYCHOTICS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

CAPLYTA, FANAPT, VRAYLAR

CRITERIA

Trial of two of the following generic formulary atypical antipsychotic agents: aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Approve for continuation of prior therapy.

BISPHOSPHONATES - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

FOSAMAX PLUS D

CRITERIA

Trial of one of the following generic formulary oral bisphosphonate agents: alendronate, ibandronate, risedronate

DPP4 INHIBITORS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

JANUMET, JANUMET XR, JANUVIA, JENTADUETO, JENTADUETO XR, TRADJENTA

CRITERIA

Trial of one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin

DPP4 INHIBITORS NON-PREFERRED - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

KOMBIGLYZE XR, ONGLYZA

CRITERIA

Trial of one of the following: Janumet, Janumet XR, Januvia, Jentadueto, Jentadueto XR, or Tradjenta

FILGRASTIM - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

GRANIX, NEUPOGEN, NIVESTYM

CRITERIA

Trial of Zarxio

GIMOTI - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

GIMOTI

CRITERIA

Trial of generic oral metoclopramide

GLOPERBA - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

GLOPERBA

CRITERIA

Trial of generic colchicine

INHALED CORTICOSTEROID - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

QVAR REDIHALER

CRITERIA

Trial of: Arnuity Ellipta and either Flovent Diskus or Flovent HFA

INJECTABLE GLP1 AGONISTS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

OZEMPIC, VICTOZA 2-PAK, VICTOZA 3-PAK

CRITERIA

Trial of one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin. Step requirements do not apply to members with type 2 diabetes and multiple cardiovascular risk factors or established cardiovascular disease.

LAMA - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

TUDORZA PRESSAIR

CRITERIA

Trial of Spiriva or Incruse Ellipta

LEUKOTRIENE MODIFIERS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

ZILEUTON ER, ZYFLO

CRITERIA

Trial of generic montelukast or generic zafirlukast

NAMZARIC - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

NAMZARIC

CRITERIA

Trial of generic memantine extended-release

NON-PREFERRED SGLT2S - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

INVOKAMET, INVOKAMET XR, INVOKANA

CRITERIA

Trial of Farxiga or Xigduo XR, AND one of the following: Jardiance, Synjardy, Synjardy XR. Step requirements do not apply to members with type 2 diabetes and diabetic nephropathy.

ORAL GLP1 AGONIST - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

RYBELSUS

CRITERIA

Trial of one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin

PD AGENTS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

NEUPRO

CRITERIA

Trial of one of the following generic formulary dopamine agonist agent: pramipexole, ropinirole

RELISTOR - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

RELISTOR

CRITERIA

Trial of Amitiza/lubiprostone and lactulose

RYTARY - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

RYTARY

CRITERIA

Trial of one generic carbidopa/levodopa containing formulation

SGLT2 DPP4 COMBO THERAPY - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

GLYXAMBI, TRIJARDY XR

CRITERIA

Trial of one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin. Step requirements do not apply to members with type 2 diabetes and multiple cardiovascular risk factors or established cardiovascular disease.

SGLT2S - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

FARXIGA, JARDIANCE, SYNJARDY, SYNJARDY XR, XIGDUO XR

CRITERIA

Farxiga, Xigduo XR (members requesting to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors will not be required to undergo this step): Trial of either A) One of the following generics: captopril, enalapril, lisinopril, quinapril, ramipril, fosinopril, trandolapril, perindopril, candesartan, valsartan, losartan, bisoprolol, carvedilol IR/ER, metoprolol succinate ER/XL, spironolactone, eplerenone, or B) one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin. Jardiance, Synjardy, Synjardy XR (members requesting to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease will not be required to undergo this step): Trial of one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin.

STATINS - SCORE

MEDICATION(S) SUBJECT TO STEP THERAPY

LIVALO

CRITERIA

Trial of any one of the following generic formulary HMG-CoA reductase inhibitors (statin): atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin